» Articles » PMID: 20512989

Inhibitory Role of Peroxisome Proliferator-activated Receptor Gamma in Hepatocarcinogenesis in Mice and in Vitro

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2010 Jun 1
PMID 20512989
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Although peroxisome proliferator-activated receptor gamma (PPARgamma) agonist have been shown to inhibit hepatocellular carcinoma (HCC) development, the role of PPARgamma in hepatocarcinogenesis remains unclear. We investigated the therapeutic efficacy of PPARgamma against HCC. PPARgamma-deficient (PPARgamma(+/-)) and wild-type (PPARgamma(+/+)) littermates were used in a diethylnitrosamine (DEN)-induced HCC model and treated with PPARgamma agonist (rosiglitazone) or the vehicle alone for 8 months. The effects of PPARgamma on HCC cell growth and apoptosis were examined using PPARgamma-expressing adenovirus (Ad-PPARgamma). PPARgamma(+/-) mice were more susceptible to DEN-induced HCC than PPARgamma(+/+) mice (94% versus 62%, P < 0.05), and rosiglitazone significantly reduced the incidence of HCC in PPARgamma(+/+) mice (vehicle 62% versus treatment 24%, P < 0.01), but not in PPARgamma(+/-) mice, indicating that PPARgamma suppresses hepatocellular carcinogenesis. A pronounced expression of PPARgamma was observed in a HCC cell line (Hep3B) infected with Ad-PPARgamma. Such induction markedly suppressed HCC cell viability (P < 0.01). Further, Hep3B infection with Ad-PPARgamma revealed a decreased proportion of cells in S-phase (12.92% versus 11.58%, P < 0.05), with arrest at G(2)/M phase (38.2% versus 55.68%, P < 0.001), and there was concomitant phosphorylation of the key G(2)/M phase inhibitors cdc25C and cdc2. PPARgamma overexpression increased cell apoptosis (21.47% versus 35.02%, P < 0.01), mediated by both extrinsic (Fas and tumor necrosis factor-alpha) and intrinsic (caspase-9, caspase-3, caspase-7, and poly[ADP-ribose] polymerase) pathways. Moreover, PPARgamma directly induced a putative tumor suppressor gene, growth differentiation factor-15.

Conclusion: Loss of one PPARgamma allele is sufficient to enhance susceptibility to HCC. PPARgamma suppresses tumor cell growth through reducing cell proliferation and inducing G(2)/M phase arrest, apoptosis, and up-regulating growth differentiation factor-15. Thus, PPARgamma acts as a tumor-suppressor gene in the liver.

Citing Articles

Identification of pyroptosis subtypes and prognosis model of hepatocellular carcinoma based on pyroptosis-related genes.

Xie H, Huang G, Mai H, Chen J, Na R, Jiang D Cancer Med. 2024; 13(15):e70081.

PMID: 39126216 PMC: 11316015. DOI: 10.1002/cam4.70081.


Pirfenidone Reverts Global DNA Hypomethylation, Promoting DNMT1/UHRF/PCNA Coupling Complex in Experimental Hepatocarcinoma.

Miranda-Roblero H, Saavedra-Salazar L, Galicia-Moreno M, Arceo-Orozco S, Caloca-Camarena F, Sandoval-Rodriguez A Cells. 2024; 13(12.

PMID: 38920644 PMC: 11201610. DOI: 10.3390/cells13121013.


GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications.

Du Y, Zhao J J Hepatocell Carcinoma. 2024; 11:1171-1183.

PMID: 38911292 PMC: 11193986. DOI: 10.2147/JHC.S471239.


Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc.

Bakiri L, Hasenfuss S, Guio-Carrion A, Thomsen M, Hasselblatt P, Wagner E Proc Natl Acad Sci U S A. 2024; 121(18):e2404188121.

PMID: 38657045 PMC: 11067056. DOI: 10.1073/pnas.2404188121.


An Overview of the Role of Peroxisome Proliferator-activated Receptors in Liver Diseases.

Changizi Z, Kajbaf F, Moslehi A J Clin Transl Hepatol. 2024; 11(7):1542-1552.

PMID: 38161499 PMC: 10752810. DOI: 10.14218/JCTH.2023.00334.